Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DY4Q6M
|
|||
| Drug Name |
Tabelecleucel
|
|||
| Synonyms |
Tab-cel
Click to Show/Hide
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Post-transplant lymphoproliferative disorder [ICD-11: 2B32; ICD-10: D47.Z1; ICD-9: 238.77] | Phase 3 | [1] | |
| Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Phase 2 | [2] | ||
| Company |
Atara Biotherapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03394365) Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.